209 related articles for article (PubMed ID: 27840422)
21. Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Akutagawa J; Huang TQ; Epstein I; Chang T; Quirindongo-Crespo M; Cottonham CL; Dail M; Slusher BS; Friedman LS; Sampath D; Braun BS
Leukemia; 2016 Jun; 30(6):1335-43. PubMed ID: 26965285
[TBL] [Abstract][Full Text] [Related]
22. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
23. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
[TBL] [Abstract][Full Text] [Related]
24. Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
Cai Z; Zhang C; Kotzin JJ; Williams A; Henao-Mejia J; Kapur R
Blood Adv; 2020 Jul; 4(14):3246-3251. PubMed ID: 32697817
[TBL] [Abstract][Full Text] [Related]
25. Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Goodwin CB; Yang Z; Yin F; Yu M; Chan RJ
Haematologica; 2012 Jul; 97(7):1042-7. PubMed ID: 22315502
[TBL] [Abstract][Full Text] [Related]
26. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
27. Exploring the effect of E76K mutation on SHP2 cause gain-of-function activity by a molecular dynamics study.
Li WY; Wei HY; Sun YZ; Zhou H; Ma Y; Wang RL
J Cell Biochem; 2018 Dec; 119(12):9941-9956. PubMed ID: 30129165
[TBL] [Abstract][Full Text] [Related]
28. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
He C; Peng Z; Zhang D; Guo Y; Liang T; Zhao Y; Yu L; Zhang Q; Chang Z; Xiao Y; Li N; Xue H; Wu S; Zhao ZJ; Zhang C; Chen Y
Biochem Pharmacol; 2023 Jul; 213():115588. PubMed ID: 37187274
[TBL] [Abstract][Full Text] [Related]
30. Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Jenkins C; Luty SB; Maxson JE; Eide CA; Abel ML; Togiai C; Nemecek ER; Bottomly D; McWeeney SK; Wilmot B; Loriaux M; Chang BH; Tyner JW
Sci Signal; 2018 Jul; 11(539):. PubMed ID: 30018082
[TBL] [Abstract][Full Text] [Related]
31. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
[TBL] [Abstract][Full Text] [Related]
32. Scaffolding protein Gab2 mediates differentiation signaling downstream of Fms receptor tyrosine kinase.
Liu Y; Jenkins B; Shin JL; Rohrschneider LR
Mol Cell Biol; 2001 May; 21(9):3047-56. PubMed ID: 11287610
[TBL] [Abstract][Full Text] [Related]
33. The tyrosine phosphatase Shp2 in development and cancer.
Grossmann KS; Rosário M; Birchmeier C; Birchmeier W
Adv Cancer Res; 2010; 106():53-89. PubMed ID: 20399956
[TBL] [Abstract][Full Text] [Related]
34. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice.
Schneeberger VE; Luetteke N; Ren Y; Berns H; Chen L; Foroutan P; Martinez GV; Haura EB; Chen J; Coppola D; Wu J
Carcinogenesis; 2014 Aug; 35(8):1717-25. PubMed ID: 24480804
[TBL] [Abstract][Full Text] [Related]
35. Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.
Mali RS; Ma P; Zeng LF; Martin H; Ramdas B; He Y; Sims E; Nabinger S; Ghosh J; Sharma N; Munugalavadla V; Chatterjee A; Li S; Sandusky G; Craig AW; Bunting KD; Feng GS; Chan RJ; Zhang ZY; Kapur R
Blood; 2012 Sep; 120(13):2669-78. PubMed ID: 22806893
[TBL] [Abstract][Full Text] [Related]
36. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
37. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.
Kharas MG; Okabe R; Ganis JJ; Gozo M; Khandan T; Paktinat M; Gilliland DG; Gritsman K
Blood; 2010 Feb; 115(7):1406-15. PubMed ID: 20008787
[TBL] [Abstract][Full Text] [Related]
38. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Schramm C; Edwards MA; Krenz M
J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
[TBL] [Abstract][Full Text] [Related]
39. Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
Thaiwong T; Sirivisoot S; Takada M; Yuzbasiyan-Gurkan V; Kiupel M
Vet Comp Oncol; 2018 Jun; 16(2):220-228. PubMed ID: 28929581
[TBL] [Abstract][Full Text] [Related]
40. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Tartaglia M; Niemeyer CM; Fragale A; Song X; Buechner J; Jung A; Hählen K; Hasle H; Licht JD; Gelb BD
Nat Genet; 2003 Jun; 34(2):148-50. PubMed ID: 12717436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]